Compare AU
Compare QYLD vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Nasdaq 100 Covered Call ETF (QYLD) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QYLD | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 13 | 63 |
Median incremental investment | $908.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,512.50 | $1,882.65 |
Average age group | > 35 | 26 - 35 |
Key Summary
QYLD | DRUG | |
|---|---|---|
Strategy | QYLD.AX was created on 2023-01-30 by Global X. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8.1m in AUM and 101 holdings. Each Fund aims to provide investors with a return (before fees and other costs) that tracks the performance of the relevant Index. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Apple Inc (8.77 %) NVIDIA Corp (8.27 %) Microsoft Corp (7.71 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Information Technology (57.72 %) Communication Services (18.86 %) Consumer Discretionary (18.11 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (97.34 %) Netherlands (0.82 %) Brazil (0.69 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.6 % | 0.57 % |
Key Summary
QYLD | DRUG | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | Cboe Nasdaq 100 Half BuyWrite V2 Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.6 % | 0.57 % |
Price | $12.10 | $8.15 |
Size | $9.461 million | $182.401 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.66 % | 1.90 % |
Market | ASX | ASX |
First listed date | 31/01/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QYLD | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 13 | 63 |
Median incremental investment | $908.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,512.50 | $1,882.65 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
QYLD | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
QYLD | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |